{"id":40120,"date":"2017-08-11T07:35:40","date_gmt":"2017-08-11T11:35:40","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=40120"},"modified":"2017-08-11T05:36:37","modified_gmt":"2017-08-11T09:36:37","slug":"biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120","title":{"rendered":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports Initiation Of ZENITH-1"},"content":{"rendered":"<p><strong>BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)<\/strong> reported the dosing of the first subject into its clinical study of ZENITH-1. This study is assessing up to 3 dosage strengths of BCX7353 administered as a single oral dose targeting acute treatment of angioedema attacks in people with hereditary angioedema.<\/p>\n<h2><strong>The details<\/strong><\/h2>\n<p>Jon Stonehouse, the Chief Executive Officer of BioCryst, reported that they are thrilled to release the ZENITH-1 exploratory Phase II study. Based upon pharmacodynamic and pharmacokinetic properties of BCX7353, they consider it could be a convenient and efficacious oral option to parenteral therapies of acute angioedema attacks in people with HAE. A liquid formulation of BCX7353 can work as a strong complement to company\u2019s prophylactic treatment program. The team consider this new formulation has the potential to fill an unmet need for people who are looking for easier and better ways to manage their ailments.<\/p>\n<p>ZENITH-1 is a randomized, placebo-controlled, double-blind, adaptive dose-ranging study of the efficacy, tolerability and safety of BCX7353 for cure of acute angioedema attacks. The trial will enroll up to 60 people with HAE. Blinded trial drug will be administered as an oral liquid after beginning of symptoms, for up to three attacks in each person, with each subject getting both placebo (for one attack) and BCX7353 (for 2 attacks) in a randomized sequence.<\/p>\n<p>The study is planned with up to 3 successive cohorts testing single doses of 250 mg (up to 12 subjects), 500 mg (up to 12 subjects) and 750 mg (from 12 to 36 subjects) starting with 750 mg. Efficacy evaluations comprise patient-reported composite VAS scores, change in symptoms, use of rescue medication and patient global assessment.<\/p>\n<p>Treatment effect will be evaluated on accumulating results, starting after 12 people have completed trial in the first cohort, by assessing the proportion of placebo-treated and BCX7353-treated attacks which have an improved or stable composite VAS at four hours post dose. Once the therapy effect is shown, registration at the 500 mg dose level will start. If therapy effect at the 500 mg dose is same as that of 750 mg, the 250 mg dose cohort is on horizon.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported the dosing of the first subject into its clinical study of ZENITH-1. This study is assessing up to 3 dosage [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":40127,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12826,8829,2868,12827,358,2869],"stock_ticker":[],"class_list":["post-40120","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-bcrx","tag-biocryst-pharmaceuticals-inc","tag-biocryst-pharmaceuticals-inc-nasdaqbcrx","tag-jon-stonehouse","tag-nasdaq","tag-nasdaqbcrx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports Initiation Of ZENITH-1 - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports Initiation Of ZENITH-1 - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported the dosing of the first subject into its clinical study of ZENITH-1. This study is assessing up to 3 dosage [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-11T11:35:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40126-g130504b.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"500\" \/>\n\t<meta property=\"og:image:height\" content=\"333\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports Initiation Of ZENITH-1\",\"datePublished\":\"2017-08-11T11:35:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120\"},\"wordCount\":345,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40126-g130504b.jpg\",\"keywords\":[\"BCRX\",\"BioCryst Pharmaceuticals Inc.\",\"BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)\",\"Jon Stonehouse\",\"NASDAQ\",\"NASDAQ:BCRX\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120\",\"name\":\"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports Initiation Of ZENITH-1 - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40126-g130504b.jpg\",\"datePublished\":\"2017-08-11T11:35:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40126-g130504b.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40126-g130504b.jpg\",\"width\":500,\"height\":333},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports Initiation Of ZENITH-1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports Initiation Of ZENITH-1 - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120","og_locale":"en_US","og_type":"article","og_title":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports Initiation Of ZENITH-1 - Wall Street PR","og_description":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported the dosing of the first subject into its clinical study of ZENITH-1. This study is assessing up to 3 dosage [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-08-11T11:35:40+00:00","og_image":[{"width":500,"height":333,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40126-g130504b.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports Initiation Of ZENITH-1","datePublished":"2017-08-11T11:35:40+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120"},"wordCount":345,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40126-g130504b.jpg","keywords":["BCRX","BioCryst Pharmaceuticals Inc.","BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)","Jon Stonehouse","NASDAQ","NASDAQ:BCRX"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120","url":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120","name":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports Initiation Of ZENITH-1 - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40126-g130504b.jpg","datePublished":"2017-08-11T11:35:40+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40126-g130504b.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/08\/40126-g130504b.jpg","width":500,"height":333},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-initiation-of-zenith-1-40120#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports Initiation Of ZENITH-1"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/40120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=40120"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/40120\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/40127"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=40120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=40120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=40120"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=40120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}